Metabolites of tamoxifen in animals and man: Identification, pharmacology, and significance

V. Craig Jordan; C. Chem.

doi:10.1007/bf01806449

journal article Jun 01, 1982

Metabolites of tamoxifen in animals and man: Identification, pharmacology, and significance

V. Craig Jordan C. Chem.

Breast Cancer Research and Treatment Vol. 2 No. 2 pp. 123-138 · Springer Science and Business Media LLC

View at Publisher Save 10.1007/bf01806449

Topics

No keywords indexed for this article. Browse by subject →

References

108

[1]

Emmens CW: Postcoital contraception. Br Med Bull 26: 45–51, 1970 10.1093/oxfordjournals.bmb.a070742

[2]

Greenblatt RB, Barfield WE, Jungck EC, Roy AW: Induction of ovulation with MRL-41. JAMA 178: 101–104, 1961 10.1001/jama.1961.03040410001001

[3]

Jensen EV, Block GE, Smith S, Kyser K, DeSombre ER: Estrogen receptors and breast cancer response to adrenalectomy. Natl Cancer Inst Mongr 34: 55–70, 1971

[4]

Herbst AL, Griffiths CT, Kistner RW: Clomiphene citrate (NSC-35770) in disseminated mammary carcinoma. Cancer Chemother Rep 43: 39–41, 1964

[5]

Cole MP, Jones CTA, Todd IDH: A new anti-oestrogenic agent in late breast cancer. Br J Cancer 25: 270–275, 1971 10.1038/bjc.1971.33

[6]

European Organisation for Research on Treatment of Cancer (EORTC) Breast Cancer Group: Clinical trial of nafoxidine, an oestrogen antagonist in advanced breast cancer. Eur J Cancer 8: 387–389, 1972 10.1016/0014-2964(72)90121-1

[7]

Ward HWC: Antioestrogen therapy for breast cancer — a trial of tamoxifen at two dose levels. Br Med J 1: 13–14, 1973 10.1136/bmj.1.5844.13

[8]

Hecker E, Vegh I, Levy CM: Clinical trial of clomiphene in advanced breast cancer. Eur J Cancer 10: 747–749, 1974 10.1016/0014-2964(74)90114-5

[9]

Bloom HJG, Boesen E: Antiestrogens in treatment of breast cancer: value of nafoxidine in 52 advanced cases. Br Med J 2: 7–10, 1974 10.1136/bmj.2.5909.7

[10]

Heuson JC, Engelsman E, Blonk-Van der Wijst J, Maass H, Drochmans A, Michel J, Nowakowski H, Gorins A: Comparative trial of nafoxidine and ethinyloestradiol in advanced breast cancer: an EORTC study. Br Med J 2: 711–713, 1975 10.1136/bmj.2.5973.711

[11]

Legha SS, Carter SK: Antiestrogens in the treatment of breast cancer. Cancer Treat Rev 3: 205–216, 1976 10.1016/s0305-7372(76)80010-2

[12]

Westerberg H: Tamoxifen and fluoxymesterone in advanced breast cancer: a controlled clinical trial. Cancer Treat Rep 64: 117–121, 1980

[13]

Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK, Nichols WC, Creagan ET, Hahn RG, Rubin J, Frytak S: Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. New Engl J Med 304: 16–21, 1981 10.1056/nejm198101013040104

[14]

Beex L, Peters G, Koenders A, Benraad T, Kloppenborg P: Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer. Cancer Treat Rep 65: 179–185, 1981

[15]

Smith IE, Harris AL, Morgan M, Ford HT, Gazel JC, Harmer CL, White H, Parsons CA, Villardo A, Walsh G, McKinna JA: Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. Br Med J 283: 1432–1434, 1981 10.1136/bmj.283.6304.1432

[16]

Mouridsen H, Palshof T, Patterson J, Battersby L: Tamoxifen in advanced breast cancer. Cancer Treat Rev 5: 131–141, 1978 10.1016/s0305-7372(78)80017-6

[17]

Heel RC, Brogden RN, Speight TM, Avery GS: Tamoxifen: a review of its pharmacological properties and therapeutic use in the treatment of breast cancer. Drugs 16: 1–24, 1978 10.2165/00003495-197816010-00001

[18]

Hubay CA, Pearson OH, Marshall JS, Rhodes RS, DeBame SM, Rosenblatt J, Mansour EG, Hermann RE, Jones JC, Flynn WJ, Eckert C, McGuire WL, and 27 participating investigators: Adjuvant chemotherapy, antiestrogen therapy and immunotherapy for stage II breast cancer. Cancer 46: 2805–2808, 1980 10.1002/1097-0142(19801215)46:12+<2805::aid-cncr2820461413>3.0.co;2-h

[19]

Fisher B, Redmond C, Brown A, Wolmark N, Wittliff J, Fisher E, Plotkin D, Bowman D, Sachs S, Wolter J, Frelick R, Desser R, LiCalzi N, Geggie P, Campell T, Elias EG, Prager D, Koontz P, Volk TT, Dimitrov N, Gardner B, Lerner H, Shibata H, and other NSABP Investigators: Treatment of primary breast cancer with chemotherapy and tamoxifen. New Eng J Med 305: 1–6, 1981 10.1056/nejm198107023050101

[20]

Katzenellenbogen BS, Bhakoo HS, Ferguson ER, Lan NC, Tatee T, Tsai TLS, Katzenellenbogen JA: Estrogen and antiestrogen action in reproductive tissues and tumors. Recent Prog Horm Res 35: 259–300, 1979

[21]

Sutherland RL, Jordan VC (eds): Nonsteroidal Antioestrogens: Molecular Pharmacology and Antitumour Activity. Academic Press, Sydney, 1981

[22]

Sutherland RL, Murphy LC: Mechanisms of oestrogen antagonism by nonsteroidal antiestrogens. Mol Cell Endocrinol 25: 5–23, 1982 10.1016/0303-7207(82)90165-4

[23]

Jordan VC: Pharmacology of antiestrogens.In DP Rose (ed): Endocrinology of Cancer III. CRC Press, Florida, 1982 pp 129–173

[24]

Harper MJK, Walpole AL: A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J Reprod Fertil 13: 101–119, 1967 10.1530/jrf.0.0130101

[25]

Terenius L: Structure—activity relationships of antioestrogens with regard to interaction with 17β-oestradiol in the mouse uterus and vagina. Acta Endocr Copenh 66: 431–447, 1971 10.1530/acta.0.0660431

[26]

Jordan VC, Rowsby L, Dix CJ, Prestwich G: Dose-related effects of non-steroidal antioestrogens and oestrogens on the measurement of cytoplasmic oestrogen receptors in the rat and mouse uterus. J Endocrinol 78: 71–81, 1978 10.1677/joe.0.0780071

[27]

Emmens CW: Compounds exhibiting prolonged antioestrogenic and antifertility activity in mice and rats. J Reprod Fertil 26: 175–182, 1971 10.1530/jrf.0.0260175

[28]

Jordan VC: Prolonged antiestrogenic activity of ICI 46, 474 in the ovariectomized mouse. J Reprod Fertil 52: 251–258, 1975 10.1530/jrf.0.0420251

[29]

Lee AE: The limitations of using mouse uterine weight as an assay of oestrogen antagonism. Acta Endocr Copenh 67: 345–352, 1971 10.1530/acta.0.0670345

[30]

Sutherland R, Mester J, Baulieu EE: Tamoxifen is a potent ‘pure’ antioestrogen in the chick oviduct. Nature (London) 267: 434–435, 1977 10.1038/267434a0

[31]

Capony F, Williams DL: Antiestrogen action in avian liver: the interaction of estrogens and antiestrogens in the regulation of apolipoprotein B synthesis. Endocrinology 108: 1862–1868, 1981 10.1210/endo-108-5-1862

[32]

Jordan VC, Koerner S: Tamoxifen as an antitumour agent: role of oestradiol and prolactin. J Endocrinol 68: 305–311, 1976 10.1677/joe.0.0680305

[33]

Jordan VC: Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 12: 419–424, 1976 10.1016/0014-2964(76)90030-x

[34]

Jordan VC, Allen KE: Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 16: 239–251, 1980. 10.1016/0014-2964(80)90156-5

[35]

Nicholson RI, Golder MP: The effect of synthetic antioestrogens on the growth and biochemistry of rat mammary tumours. Eur J Cancer 11: 571–579, 1975 10.1016/0014-2964(75)90129-2

[36]

Jordan VC, Jaspan T: Tamoxifen as an antitumour agent: oestrogen binding as a predictive test for tumour response. J Endocrinol 68: 453–460, 1976 10.1677/joe.0.0680453

[37]

Manni A, Trujillo JE, Pearson OH: Predominant role of prolactin in stimulating the growth of 7,12-dimethylbenz(a)anthracene-induced rat mammary tumor. Cancer Res 37: 1216–1219, 1977

[38]

Welsch CW, Goodrich-Smith M, Brown CK, Miglorie N, Clifton KH: Effect of an estrogen antagonist (tamoxifen) on the initiation and progression ofγ-irradiation-induced mammary tumors in female Sprague-Dawley rats. Eur J Cancer Clin Oncol 17: 1255–1258, 1981 10.1016/0014-2964(81)90004-9

[39]

Holinka CF, Bressler RS, Zehr DR, Gurpide E: Comparison of effects of estetrol and tamoxifen with those of estradiol on the immature rat uterus. Biol Reprod 22: 913–926, 1980 10.1095/biolreprod22.4.913

[40]

Jordan VC, Prestwich G, Dix CJ, Clark ER: Binding of antiestrogens to the estrogen receptor, the first step in antiestrogen action.In E Genazzani, F DiCarlo, and WIP Mainwaring (eds): Pharmacological Modulation of Steroid Action. Raven Press, New York, 1980, pp 81–98

[41]

Koseki Y, Zava DT, Chamness GC, McGuire WL: Progesterone interaction with estrogen and antiestrogen in the rat uterus — receptor effects. Steroids 30: 169–177, 1977 10.1016/0039-128x(77)90079-4

[42]

Dix CJ, Jordan VC: Modulation of rat uterine steroid hormone receptors by estrogen and antiestrogen. Endocrinology 107: 2011–2020, 1980 10.1210/endo-107-6-2011

[43]

Bulger WH, Kupfer D: Induction of uterine ornithine decarboxylase (ODC) by antiestrogens: inhibition of estradiol-mediated induction of ODC: a possible mechanism of action of antiestrogens. Endocrine Res Comm 3: 209–218, 1976 10.3109/07435807609056901

[44]

Bichon M, Bayard F: Dissociated effects of tamoxifen and oestradiol-17β on uterus and liver functions. J Steroid Biochem 10: 105–107, 1979 10.1016/0022-4731(79)90149-3

[45]

Kreifel MA, Katzenellenbogen BS: Comparative effects of estrogen and antiestrogen on plasma renin substrate levels and hepatic estrogen receptors in the rat. Endocrinology 108: 545–552, 1981 10.1210/endo-108-2-545

[46]

Jordan VC, Dix CJ, Allen KE: Effects of antioestrogens in carcinogen-induced rat mammary cancer.In RL Sutherland and VC Jordan (eds): Nonsteroidal Anti-oestrogens. Academic Press, Sydney, 1981, pp 261–280

[47]

Hahnel R, Twaddle E, Ratajczak T: The influence of synthetic antiestrogens on the binding of [3H]estradiol-17β by cytosols of human uterus and human breast carcinoma. J Steroid Biochem 4: 687–695, 1973 10.1016/0022-4731(73)90044-7

[48]

Jordan VC, Koerner S: Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor. Eur J Cancer 11: 205–206, 1975 10.1016/0014-2964(75)90119-x

[49]

Lerner HJ, Band PR, Israel L, Leung BS: Phase II study of tamoxifen: report of 74 patients with stage IV breast cancer. Cancer Treat Rep 60: 1431–1435, 1976

[50]

Morgan LR, Schein PS, Woolley PV, Hoth D, Mac Donald J, Lippman M, Posey LE, Beazley RW: Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters. Cancer Treat Rep 60: 1437–1443, 1976

Showing 50 of 108 references

Metrics

113

Citations

108

References

Details

Published: Jun 01, 1982
Vol/Issue: 2(2)
Pages: 123-138
License: View

Authors

Cite This Article

V. Craig Jordan, C. Chem. (1982). Metabolites of tamoxifen in animals and man: Identification, pharmacology, and significance. Breast Cancer Research and Treatment, 2(2), 123-138. https://doi.org/10.1007/bf01806449

Metabolites of tamoxifen in animals and man: Identification, pharmacology, and significance

You May Also Like